Page last updated: 2024-10-31

molsidomine and Fibrosis

molsidomine has been researched along with Fibrosis in 4 studies

Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

Research Excerpts

ExcerptRelevanceReference
" We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies."7.79The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013)
"NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis."7.72NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003)
"Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart."3.85Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017)
" We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies."3.79The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013)
"•  To investigate whether sustained long-term separate treatments of diabetic inducible nitric oxide synthase knockout (iNOSKo) mice with allopurinol, an antioxidant inhibiting xanthine oxidoreductase, decorin, a transforming growth factor-β1 (TGFβ1) -binding antagonist, and molsidomine, a long-life nitric oxide donor, prevent the processes of diabetes-induced cavernosal fibrosis."3.78Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. ( Ferrini, MG; Gonzalez-Cadavid, NF; Moon, J; Rajfer, J; Rivera, S, 2012)
"NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis."3.72NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zordan, P1
Sciorati, C1
Campana, L1
Cottone, L1
Clementi, E1
Querini, PR1
Brunelli, S1
Oosterhuis, NR1
Bongartz, LG1
Verhaar, MC1
Cheng, C1
Xu, YJ1
van Koppen, A1
Cramer, MJ1
Goldschmeding, R1
Gaillard, CA1
Doevendans, PA1
Braam, B1
Joles, JA1
Ferrini, MG1
Moon, J1
Rivera, S1
Rajfer, J1
Gonzalez-Cadavid, NF1
Peters, H1
Daig, U1
Martini, S1
Rückert, M1
Schäper, F1
Liefeldt, L1
Krämer, S1
Neumayer, HH1

Other Studies

4 other studies available for molsidomine and Fibrosis

ArticleYear
The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy.
    European journal of pharmacology, 2013, Sep-05, Volume: 715, Issue:1-3

    Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Immunity, Innate; Inflammation; Mice; Molsidomine

2013
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
    Acta physiologica (Oxford, England), 2017, Volume: 220, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess

2017
Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.
    BJU international, 2012, Volume: 109, Issue:4

    Topics: Allopurinol; Animals; Antioxidants; Apoptosis; Decorin; Diabetes Mellitus, Experimental; Enzyme Inhi

2012
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
    Kidney international, 2003, Volume: 64, Issue:2

    Topics: Animals; Arginine; Blood Pressure; Body Weight; Enzyme Inhibitors; Fibronectins; Fibrosis; Gene Expr

2003